MRNA · News · 20261112N

Operating Expense Trends

Moderna, Inc. · 2026-11-12 · Importance 64 · Surprise 42 · In source text

Moderna set a 2027 cash cost target of about $4 billion at its 2026 Analyst Day. Quantisnow reported that this target exceeded the midpoint of the company’s previous guidance. The report linked increased expected spending particularly to oncology investment and said the company did not provide a 2027 revenue forecast. Other reporting said Moderna plans to increase oncology investment through 2030.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
operating_incomenegativecommitted—Moderna's approximately $4 billion 2027 cash cost target exceeded the midpoint of its previous guidance.
cashnegativecommitted—Moderna's approximately $4 billion 2027 cash cost target exceeded the midpoint of its previous guidance.